MGNX

MacroGenics Inc. (MGNX) | Rumor.io

MacroGenics

MGNX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,907

Bullish sentiment (50-day avg)84%

Price to earnings ratio25.3

Market capitalization258.6M

Earnings per share-1.59

Dividend yield (TTM)—

Revenue (annual)149.5M

Net income (annual)-74.6M

Social

What share of all stock conversation is about MGNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Jun 22

MacroGenics, Inc. (MGNX) will receive a $24.5 million regulatory milestone payment from Sanofi due to the accelerated approval of Tzield for type 1 diabetes in patients aged 8-17.
The payment is one of several potential milestones MacroGenics could receive from Sanofi, totaling up to $305 million.
The company's cash position is now significantly increased, with a per-share value of over $5, providing a potential upside for investors.

Generated by AI

Sentiment

Of the messages about MGNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	35.71%	55% -39.34	86.69% +14.44
Bearish	100%	64.29%	45% +39.34	13.31% -14.44

Bullish· May 12

$MGNX has a strong short-term breakout and bullish signal, with a 26.78% increase in after-hours trading.
The company's new CEO is dynamic and will not let long time lapses in story, with the deal today allowing MacroGenics to access manufacturing facilities for all their projects.
MacroGenics has a solid balance sheet, with pro forma cash of around $330 million, and is undervalued, with a price-to-cash ratio of 0.65x, allowing it to trade at much higher levels.

Bearish· Jun 10

MacroGenics, Inc. (MGNX) is experiencing a significant disconnect between its cash reserves and stock price, with the company holding $70M in cash but only seeing its value appreciate by $25M.
Despite having a major pipeline and multiple royalty-paying drugs, MGNX is struggling to hold above $2 per share, suggesting that the stock may be undervalued or subject to manipulation.
The company's cash reserves and pipeline of future royalty and milestone payments make it an attractive acquisition target, yet MGNX is trading at a ridiculously low price, making it a prime candidate for a takeover.

Generated by AI

Topics

Of the messages about MGNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	77.51%
Technical Analysis	—	—	0%	8.41%
Analysts	—	—	0%	7.77%
Controversies	—	—	0%	1.62%
Earnings	—	—	0%	0.49%
Macro	—	—	0%	4.21%

Earnings· Aug 7

MacroGenics, Inc. ($MGNX) beats EPS loss estimates by $0.19 and beats on revenues.
$MGNX reports FQ2 earnings of $-1.03 EPS and $18.83M Revs, beating Estimize Consensus by 21c and $14.80M respectively.
$MGNX reported a loss of $1.03, beating consensus estimate of ($1.20) via #epsbeat.

Analysts· May 12

Credit Suisse raised MacroGenics' price target to $30, maintaining an outperform rating.
Analysts are mildly confident about MacroGenics, with a 77% buy consensus among 7 analysts.
SVB Leerink raised Q2 2020 EPS estimates for MacroGenics, Inc.

Announcements· May 12

MacroGenics, Inc. ($MGNX) has entered into a definitive agreement to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfront payment.
The sale includes the company's Rockville, Maryland FDA-approved facility and Frederick warehouse, and is expected to close in Q3 2026.
The deal will strengthen MacroGenics' balance sheet and allow the company to focus on its pipeline of cancer therapies, with the potential for future milestone payments.

Technical Analysis· Mar 10

$MGNX has broken through the $2.60 resistance on high volume, signaling a powerful momentum shift with a surge of +27.11%.
Technical analysis indicates a momentum shift with a potential target at $4.04, supported by upcoming catalysts, and a strong entry point for investors.
The rising trend for $MGNX looks set to expand, with an initial target above $4 and a strong momentum indicator suggesting a continued uptrend.

Generated by AI

Community

Of the messages about MGNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	98.08%	88.24%	63.51%
Newcomers	0%	1.92%	11.76%	36.49%

Regulars· May 12

$MGNX is experiencing a wide channel in its price movement, with regulars noting a bullish pennant and a possible falling wedge.
The recent partnership with Bora, which acquired MacroGenics' manufacturing site for $122.5M, has lessened MGNX's operational expenses and suggests the company is not considering an acquisition anytime soon.
The focus is on MGNX's pipeline, particularly its partnered asset ZYNYZ, which could be worth $200M and has the potential for a $1.6B payment from GILD if approvals are received.

Newcomers· May 12

Newcomers are focused on the stock's recent price movement, with some discussing its potential to break above $3.75.
The sale of MacroGenics' GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million is being seen as a positive development, with some anticipating a price increase to $4.50 or $4.85.
The company's cash reserves and market capitalization are being highlighted, with some noting that MacroGenics has around $6 in cash and a market cap of $187.50 million.

Generated by AI

ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations

20d agofinance.yahoo.com

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX)

20d agoSeeking Alpha

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.

1mo agoYahoo Finance

Macrogenics senior VP sells $129,085 in shares

1mo agoInvesting.com

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)’s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies’ 2022 collaboration. That broader agreement spans three programs, including clinical-stage CD123 x CD3 […]

1mo agoYahoo Finance

Also Discussed

Investors talking about MGNX also mention

#	Name	Attention
1	Xencor Inc.XNCR	0%new
2	Protagonist Therapeutics, Inc.PTGX	0%new
3	Syndax Pharmaceuticals, Inc.SNDX	0%+0
4	BPMC - Blueprint Medicines Corporation	——
5	Zai Lab Limited ADRZLAB	0%0
6	Mirum Pharmaceuticals, Inc.MIRM	0%0
7	JNCE - Jounce Therapeutics, Inc.	——
8	Karyopharm Therapeutics Inc.KPTI	0%new
9	MRTX - Mirati Therapeutics, Inc.	——
10	Bicycle Therapeutics plc - ADRBCYC	0%0

MacroGenics Inc.

Healthcare
Biotechnology

MacroGenics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics for cancer. Its current portfolio centers on advanced biologics platforms, including antibody-drug conjugates, bispecific checkpoint antibodies, and next-generation T-cell engagers, which support a pipeline of product candidates in clinical testing. The company’s work includes therapies designed to target specific tumor markers and modulate immune responses across a range of oncology settings. MacroGenics also maintains collaborations with other biotechnology and pharmaceutical companies to support development across its programs. Headquartered in Rockville, Maryland, MacroGenics plays a specialized role in the oncology market by advancing precision antibody technologies intended for use in difficult-to-treat cancers.

Website

Location

9704 Medical Center Drive

Rockville, MD, 20850

United States

Social

What share of all stock conversation is about MGNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Jun 22

MacroGenics, Inc. (MGNX) will receive a $24.5 million regulatory milestone payment from Sanofi due to the accelerated approval of Tzield for type 1 diabetes in patients aged 8-17.
The payment is one of several potential milestones MacroGenics could receive from Sanofi, totaling up to $305 million.
The company's cash position is now significantly increased, with a per-share value of over $5, providing a potential upside for investors.

Generated by AI

Sentiment

Of the messages about MGNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	35.71%	55% -39.34	86.69% +14.44
Bearish	100%	64.29%	45% +39.34	13.31% -14.44

Bullish· May 12

$MGNX has a strong short-term breakout and bullish signal, with a 26.78% increase in after-hours trading.
The company's new CEO is dynamic and will not let long time lapses in story, with the deal today allowing MacroGenics to access manufacturing facilities for all their projects.
MacroGenics has a solid balance sheet, with pro forma cash of around $330 million, and is undervalued, with a price-to-cash ratio of 0.65x, allowing it to trade at much higher levels.

Bearish· Jun 10

MacroGenics, Inc. (MGNX) is experiencing a significant disconnect between its cash reserves and stock price, with the company holding $70M in cash but only seeing its value appreciate by $25M.
Despite having a major pipeline and multiple royalty-paying drugs, MGNX is struggling to hold above $2 per share, suggesting that the stock may be undervalued or subject to manipulation.
The company's cash reserves and pipeline of future royalty and milestone payments make it an attractive acquisition target, yet MGNX is trading at a ridiculously low price, making it a prime candidate for a takeover.

Generated by AI

Topics

Of the messages about MGNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	77.51%
Technical Analysis	—	—	0%	8.41%
Analysts	—	—	0%	7.77%
Controversies	—	—	0%	1.62%
Earnings	—	—	0%	0.49%
Macro	—	—	0%	4.21%

Earnings· Aug 7

MacroGenics, Inc. ($MGNX) beats EPS loss estimates by $0.19 and beats on revenues.
$MGNX reports FQ2 earnings of $-1.03 EPS and $18.83M Revs, beating Estimize Consensus by 21c and $14.80M respectively.
$MGNX reported a loss of $1.03, beating consensus estimate of ($1.20) via #epsbeat.

Analysts· May 12

Credit Suisse raised MacroGenics' price target to $30, maintaining an outperform rating.
Analysts are mildly confident about MacroGenics, with a 77% buy consensus among 7 analysts.
SVB Leerink raised Q2 2020 EPS estimates for MacroGenics, Inc.

Announcements· May 12

MacroGenics, Inc. ($MGNX) has entered into a definitive agreement to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfront payment.
The sale includes the company's Rockville, Maryland FDA-approved facility and Frederick warehouse, and is expected to close in Q3 2026.
The deal will strengthen MacroGenics' balance sheet and allow the company to focus on its pipeline of cancer therapies, with the potential for future milestone payments.

Technical Analysis· Mar 10

$MGNX has broken through the $2.60 resistance on high volume, signaling a powerful momentum shift with a surge of +27.11%.
Technical analysis indicates a momentum shift with a potential target at $4.04, supported by upcoming catalysts, and a strong entry point for investors.
The rising trend for $MGNX looks set to expand, with an initial target above $4 and a strong momentum indicator suggesting a continued uptrend.

Generated by AI

Community

Of the messages about MGNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	98.08%	88.24%	63.51%
Newcomers	0%	1.92%	11.76%	36.49%

Regulars· May 12

$MGNX is experiencing a wide channel in its price movement, with regulars noting a bullish pennant and a possible falling wedge.
The recent partnership with Bora, which acquired MacroGenics' manufacturing site for $122.5M, has lessened MGNX's operational expenses and suggests the company is not considering an acquisition anytime soon.
The focus is on MGNX's pipeline, particularly its partnered asset ZYNYZ, which could be worth $200M and has the potential for a $1.6B payment from GILD if approvals are received.

Newcomers· May 12

Newcomers are focused on the stock's recent price movement, with some discussing its potential to break above $3.75.
The sale of MacroGenics' GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million is being seen as a positive development, with some anticipating a price increase to $4.50 or $4.85.
The company's cash reserves and market capitalization are being highlighted, with some noting that MacroGenics has around $6 in cash and a market cap of $187.50 million.

Generated by AI

MacroGenics

Social

Jun 22

Bullish· May 12

Bearish· Jun 10

Earnings· Aug 7

Analysts· May 12

Announcements· May 12

Technical Analysis· Mar 10

Regulars· May 12

Newcomers· May 12

MacroGenics at H.C. Wainwright conference: leaner model, rich pipeline

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX)

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Macrogenics senior VP sells $129,085 in shares

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

Also Discussed

MacroGenics Inc.

Company Information

Location

MacroGenics at H.C. Wainwright conference: leaner model, rich pipeline

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX)

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Macrogenics senior VP sells $129,085 in shares

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

Also Discussed

Social

Jun 22

Bullish· May 12

Bearish· Jun 10

Earnings· Aug 7

Analysts· May 12

Announcements· May 12

Technical Analysis· Mar 10

Regulars· May 12

Newcomers· May 12